DIALYSIS IN AFRICA — QUESTIONS THAT MATTER
These are the questions operators, investors, and procurement teams across Africa are actually asking.
The answers are based on 25 years of working inside these markets — not observing them from the outside.
COST AND PROCUREMENT
How do dialysis clinics reduce treatment costs in Africa without switching products or machines?
The cost problem in most African dialysis operations is not the product. It is the structure around the product. Reactive procurement — ordering when stock runs low rather than planning against patient volume — consistently inflates both unit cost and freight cost at the same time. Warehouse-model distributors add a second shipping leg, a second customs clearance, and warehouse overhead to every order. None of this appears as a line item. It simply becomes the price you pay.
Operators who have reduced total treatment cost significantly have done so by restructuring three things: removing the warehouse intermediary and moving to direct-shipment supply, switching from liquid to dry concentrate to reduce freight volume, and planning supply cycles against actual treatment demand rather than reacting to stock levels.
The product does not change. The cost structure does.
See how supply restructuring works in practice →
Why do emergency dialysis supply orders cost more — and how do you eliminate them?
Emergency orders cost 20 to 40 per cent more than planned orders. That premium is not negotiable. A supplier filling an urgent order charges for urgency — faster freight, priority handling, and the operational disruption of fulfilling outside of a normal cycle. For a 10-station clinic running 6,240 sessions annually, two or three emergency orders a year adds over USD 6,800 to supply cost before any other variable is counted.
Emergency orders are almost always the result of a planning gap, not a supply failure. When supply cycles are not aligned to actual patient volume, stock runs low unpredictably. The fix is not faster emergency ordering. It is eliminating the conditions that create the emergency in the first place.
Operators who restructure supply planning to align with their treatment schedule — rather than ordering by gut feel or when shelves look thin — typically eliminate emergency orders within six months.
How we structure supply cycles →
How does port delay and shipping cycle length affect dialysis supply costs in Africa?
Port delays in East and West Africa are not exceptions. They are a normal operating condition. An order that takes six weeks in a predictable freight environment can take ten to fourteen weeks when port congestion, customs disputes, or documentation errors occur. For a clinic running on a thin stock buffer, that gap has direct clinical consequences.
The answer is not to hold more stock — excess stock creates its own cost through tied-up capital, storage pressure, and expiry risk. The answer is to build supply cycles that account for realistic freight timelines rather than optimistic ones, and to structure order quantities so that a delayed shipment does not immediately create a clinical risk.
Supply models that are not designed around African port reality will always be exposed to it.
How does currency pressure affect dialysis costs in Africa, and what can operators do about it?
Most dialysis consumables are priced in USD. Most African operators collect revenue in local currency. When a currency devalues — which in markets like Nigeria, Ghana, Uganda and Kenya happens with regularity — the cost of the next order rises in local currency terms even if the USD price has not moved. This risk does not appear in the cost-per-session figure until the moment a devaluation event occurs.
The structural response is to reduce the length of the payment cycle and reduce the total volume of USD exposure at any one time. Smaller, more frequent direct shipments reduce the amount of currency exposure on any single order. Dry concentrate also reduces the total USD cost of freight significantly — less volume to ship means less USD exposure on logistics.
There is no way to eliminate currency risk entirely. There are ways to reduce the size of the exposure.
What is the real cost per dialysis session in Africa — and why is it higher than it should be?
The visible cost — the price of a dialyzer, a blood line set, a concentrate canister — is only part of what a session actually costs. The hidden costs accumulate in the supply chain around the product: freight volatility, emergency order premiums, warehouse markups, customs delays, currency exposure, and the administrative cost of reactive procurement management.
Studies across sub-Saharan Africa indicate that more efficient procurement strategies alone can reduce dialysis supply costs by up to 30 per cent — not through cheaper products, but through removing the layers of cost that sit between the manufacturer and the clinic. SHK Medical has achieved reductions of up to 31 per cent across multiple African and Caribbean markets through direct-shipment models, dry concentrate conversion, and demand-aligned supply planning.
The unit price is rarely where the money is going.
SUPPLY STRUCTURE AND LOGISTICS
What is the difference between liquid and dry dialysis concentrate — and why does it matter for African operators?
Dialysis concentrate is required for every single treatment session without exception. The question is what form it takes when it travels to your clinic.
Liquid concentrate is approximately 90 per cent water. It is heavy, bulky, and expensive to freight. Four shipping containers of liquid concentrate deliver what one container of dry powder mix reconstitutes to — the same number of treatment-ready canisters, the same clinical output. For markets where freight costs are already disproportionately high and port delays are a normal risk, the volume difference is not a minor efficiency. It is one of the largest single structural cost levers available to an operator.
Dry concentrate — powder mixed with purified water at the clinic — requires a mixing step but delivers the same clinical result. For clinics with adequate water treatment infrastructure, the conversion from liquid to dry is one of the most direct cost reductions available without changing any clinical protocol.
How do you plan dialysis supply around long freight cycles in Sub-Saharan Africa?
The starting point is actual treatment data, not estimates. How many sessions does the clinic run per week? How many patients are on a three-times-weekly schedule? What is the realistic freight timeline from order to clinic — accounting for port congestion, not the freight company's optimistic estimate?
From those three numbers, a supply cycle can be built that holds a realistic buffer without over-stocking. The buffer needs to cover the realistic worst-case transit time, not the average. In most East African markets, planning for a twelve-week cycle is more honest than planning for six.
The clinics that run out of stock are almost never clinics that experienced a genuine supply failure. They are clinics whose planning assumptions were built on best-case transit times that did not survive contact with reality.
Are OEM-compatible dialysis consumables clinically safe, and can they be used with existing machines?
OEM-compatible does not mean generic or substandard. It means manufactured to the same specifications that the original equipment manufacturer requires for their own machines — the same dimensions, the same material standards, the same sterilisation protocols.
Every consumable SHK Medical supplies is OEM-approved and compatible with all major dialysis machine platforms, including Fresenius, Baxter, Nipro, B.Braun, Nikkiso, Gambro, Bellco, Dora, SWS, and Dialife. Clinics do not need to change machines, change protocols, or accept any reduction in clinical standard. The product performs to the same specification. The cost structure is different.
For operators concerned about compatibility before committing to a supply change, SHK Medical provides compatibility confirmation by machine model before any order is placed.
SETTING UP A DIALYSIS FACILITY IN AFRICA
What does it cost to set up a dialysis centre in Africa?
There is no single answer — and any supplier or consultant who gives you one without understanding your market, your patient volume projections, your water quality, your regulatory environment, and your infrastructure starting point is giving you a number that will not survive the first site visit.
The real question is not what it costs to install a dialysis unit. It is what it costs to build a dialysis operation that functions under the conditions that actually exist in your location. Machines that work in a controlled European environment behave differently in a location with variable power, variable water quality, and limited technical support availability.
The conversations worth having before any capital is committed are about operational readiness — not installation cost. What happens on day 91 when the first service issue occurs? What is the supply chain for consumables? What is the water treatment strategy? What does commissioning and staff training look like in practice?
How we approach facility setup →
What are the most common reasons dialysis facilities fail in Africa — and how are they avoided?
The failure points are almost never the ones that appear in a feasibility study. Machines fail in water environments they were not designed for. Supply chains that looked adequate on paper collapse under the first port delay. Staff trained at commissioning turn over before the second year. The facility that looked operational on opening day has quietly started degrading six months later — and nobody named it until it became a crisis.
The operators who avoid these outcomes share one characteristic: they planned for operational reality, not installation success. They built their water treatment to handle local water quality, not theoretical standards. They built their supply model around realistic freight timelines. They planned staff retention and ongoing training from the start, not as an afterthought.
Building a dialysis facility in Africa is not a procurement project. It is an operational infrastructure project that happens to begin with procurement.
See what clinical turnkey delivery includes →
Is there genuine demand for private dialysis in Africa — and is it a viable investment?
Chronic kidney disease affects over 100 million people across Africa. The gap between the number of patients who need dialysis and the number who currently receive it is one of the largest unmet healthcare needs on the continent. In most sub-Saharan African countries, the public health system cannot absorb that demand — waiting lists are long, machines are limited, and government capacity is under sustained pressure.
Private dialysis operations in markets like Kenya, Nigeria, Ghana, Uganda, and Rwanda are not competing with an oversupplied system. They are addressing a structural deficit. The investment case exists. The challenge is operational execution — building a facility that can run sustainably, control its supply costs, and maintain clinical standards in an environment that tests every assumption.
The demand is real. The question is whether the operational model is built to survive contact with that environment.
LOCAL DIALYSIS CONCENTRATE PRODUCTION
Can dialysis concentrate be produced locally in Africa — and is it clinically acceptable?
Yes. Dialysis concentrate — both acid and bicarbonate — can be produced locally in Africa using established pharmaceutical mixing and production processes. The clinical output is identical to imported concentrate provided the production process meets the relevant quality standards and the water used in production is adequately purified.
Local production is already operational in multiple emerging markets. It is not an experimental model. It is a proven approach to permanently reducing one of the largest recurring cost lines in a dialysis operation.
What are the cost benefits of local dialysis concentrate production compared to importing?
The freight cost of importing liquid dialysis concentrate is disproportionate to its clinical value. Liquid concentrate is approximately 90 per cent water — meaning the majority of the freight cost is the cost of shipping water. Local production eliminates that cost permanently.
For a country or hospital group running hundreds of dialysis sessions per day, the recurring import cost for liquid concentrate is one of the largest single recurring drains on the healthcare budget. Local production converts that into a fixed infrastructure cost that reduces the per-session consumable cost significantly and removes the freight, port delay, and currency exposure risk from concentrate supply entirely.
The economics of local production are most compelling at scale — for hospital groups, government health ministries, and healthcare investors operating or planning to operate multiple facilities.
What is needed to produce dialysis concentrate locally — and who is this relevant for?
Local production requires pharmaceutical-grade water treatment infrastructure, a controlled mixing environment, quality testing capability, and a distribution model to move concentrate from the production point to treatment facilities. It is a production and logistics infrastructure project, not a procurement decision.
It is most relevant for healthcare investors building or managing multiple dialysis facilities, government health ministries looking to reduce national dialysis supply costs permanently, and established hospital groups where the volume justifies the infrastructure investment.
SHK Medical provides turnkey local production capability — from feasibility assessment through facility design, equipment supply, commissioning, staff training, and quality system setup.
See what local production setup includes →
Why is dialysis supply disproportionately expensive on Caribbean islands — and what changes it?
Running dialysis on an island means every consumable arrived by sea or air. There is no regional warehouse to draw from. No emergency supplier two hours away by road. When a shipment is delayed, the clinic feels it the same day.
The cost problem is structural. Small-volume orders on island logistics carry freight cost per unit that mainland operators never encounter. A single pallet of consumables shipped to Trinidad costs a disproportionate multiple of what the same pallet costs to move within a continental supply network. Multiply that across every order cycle in a year and the freight premium becomes one of the largest cost lines in the operation — not the product itself.
The operators who have resolved this have done it the same way: consolidating order frequency, increasing order volume per shipment to reduce the per-unit freight cost, and switching to dry concentrate to eliminate the single heaviest, bulkiest item in the shipment.
In Port of Spain, Trinidad, restructuring supply to a direct-shipment model reduced total treatment cost by 35 per cent. Those savings were reinvested directly into patient programmes.
How the Caribbean supply model works →
What is Citrasate — and why does it matter for Caribbean and African dialysis operators?
Citrasate is a citrate-based dialysis acid concentrate. It replaces the acetic acid used in standard dialysate with citrate — a change that has measurable clinical benefits, including reduced systemic anticoagulation requirements, lower rates of intradialytic symptoms, and improved biocompatibility.
What distinguishes Citrasate from any other concentrate option is its evidence base. Citrasate has accumulated over 30 years of peer-reviewed clinical testing. No other dialysis concentrate in the market has been subjected to that level of sustained, independent clinical analysis — and the conclusions across that body of research are virtually consistent. The clinical case is not disputed.
Citrasate is USFDA-registered. In markets where regulatory credibility and clinical accountability matter — and in both Africa and the Caribbean, they matter significantly — that registration is not a formality. It is a documented quality standard that most concentrate options available in these markets cannot match.
SHK Medical supplies Citrasate at bulk scale, available to clinics across Africa and the Caribbean.
How does consolidating dialysis supply orders reduce freight cost for Caribbean operators?
Every shipment to an island carries a fixed freight cost regardless of what is in it. The larger the order per shipment, the lower the cost per unit. The smaller the order, the more of that fixed cost each unit carries.
Most Caribbean operators order reactively — when stock is running low, they place an order. The result is frequent small shipments, each carrying a disproportionate freight burden. Restructuring to less frequent, larger consolidated orders — planned against actual patient volume rather than stock anxiety — reduces the per-unit landed cost materially.
The additional step that changes the freight equation most significantly is switching from liquid to dry concentrate. Liquid concentrate is the heaviest, bulkiest item in a dialysis supply shipment. Removing it — or converting to Citrasate in dry form — reduces the volume and weight of every shipment, which reduces the freight cost of every other item in it simultaneously.
The product cost does not change. The total landed cost does.
Why do Caribbean operators run out of dialysis supplies — and how is it prevented?
The cause is almost always the same: supply planning built around best-case shipping timelines rather than realistic ones. A sea freight shipment that takes three weeks under normal conditions takes six when a vessel is delayed, a port is congested, or a documentation issue stalls customs clearance. A clinic holding two weeks of buffer stock on a three-week transit assumption has no room for any of that.
Island operators need buffer stock calculated against realistic worst-case transit times — not the freight forwarder's quoted standard. That means holding more inventory than feels comfortable, which requires the order volume and cash flow structure to support it.
The alternative — air freight when sea freight is delayed — costs multiples of sea freight rates and erodes margin on every session until the next planned shipment arrives.
Planning for the realistic scenario rather than the optimistic one is not pessimism. It is what keeps patients on schedule.
FOR DISTRIBUTORS
These answers reflect 25 years of operating inside the markets they describe.
Not from a distribution centre in Europe with a map of Africa on the wall. From inside the port disputes, the customs delays, the currency devaluations, and the supply emergencies that these questions are actually about.
If a question here is relevant to what you are dealing with — or if the situation you are managing does not fit neatly into any of these answers — the most useful next step is a direct conversation.
How do dialysis consumable distributors protect their margins in African markets?
Margin erosion for dialysis distributors in African markets typically comes from two directions: price pressure from clinic operators who are themselves under cost pressure, and supply volatility that creates emergency procurement situations where the distributor absorbs cost rather than passing it on.
The distributors who maintain margin consistently are those who have locked in supply stability — predictable pricing, reliable delivery cycles, and a product range that covers the machine platforms their clients operate. When supply is stable and price is predictable, margin conversations become easier because the value is visible.
OEM-Approved Consumables · Integrated Logistics · Cost Stability at Scale · Local Production
© 2026. All rights reserved.
info@shkmedical.com